Siponimod fumarate (BAF-312) is a synthetic sphingosine 1- phosphate (S1P) receptor modulator, which exerts immunomodulating effects mediated by B- and T-cell sequestration in secondary lymphoid organs. S1P receptor modulators have consistently shown a significant benefit on relapse rate and other measures of disease activity in patients with relapsing multiple sclerosis (MS), compared with both placebo and active comparator. However, most clinical trials of S1P receptor modulators--as well as other therapies for MS--lack evidence of a significant benefit on disability progression. A phase III trial of siponimod for secondary progressive MS showed a significant effect of the active drug compared with placebo on reduction of disability progr...
BACKGROUNDSiponimod (BAF312) is a selective sphingosine-1-phosphate receptor 1 and 5 (S1PR1, S1PR5) ...
Multiple sclerosis (MS) is an immune-mediated disorder of the CNS manifested by recurrent attacks of...
Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis...
Alberto Gajofatto Department of Neuroscience, Biomedicine and Movement Sciences, University of Vero...
Patients with multiple sclerosis (MS) are at high risk for transition to secondary progressive MS (S...
Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P1) and 5 (S1P5) modulator ap...
Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P1) and 5 (S1P5) modulator ap...
Background No treatment has consistently shown efficacy in slowing disability progression in patient...
BackgroundSiponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary pr...
Siponimod, a selective modulator of sphingosine 1-phosphate receptors 1 (S1P1) and 5 (S1P5), has rec...
BACKGROUNDSiponimod (BAF312) is a selective sphingosine-1-phosphate receptor 1 and 5 (S1PR1, S1PR5) ...
Multiple sclerosis (MS) is an immune-mediated disorder of the CNS manifested by recurrent attacks of...
Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis...
Alberto Gajofatto Department of Neuroscience, Biomedicine and Movement Sciences, University of Vero...
Patients with multiple sclerosis (MS) are at high risk for transition to secondary progressive MS (S...
Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P1) and 5 (S1P5) modulator ap...
Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P1) and 5 (S1P5) modulator ap...
Background No treatment has consistently shown efficacy in slowing disability progression in patient...
BackgroundSiponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary pr...
Siponimod, a selective modulator of sphingosine 1-phosphate receptors 1 (S1P1) and 5 (S1P5), has rec...
BACKGROUNDSiponimod (BAF312) is a selective sphingosine-1-phosphate receptor 1 and 5 (S1PR1, S1PR5) ...
Multiple sclerosis (MS) is an immune-mediated disorder of the CNS manifested by recurrent attacks of...
Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis...